Move FM Global News

WASHINGTON, D.C.: The U.S. Food and Drug Administration (FDA) said this week it will start using artificial intelligence (AI) in all its departments right away, with full use beginning on June 30.

This follows a successful test of AI tools designed to assist scientists in reviewing new drugs.

When the FDA gets a new drug application, it usually takes 6 to 10 months to decide whether to approve it. The latest AI tools will help experts spend less time on tedious, repetitive tasks that slow down the process.

The FDA stated that it will continue to improve the system to make it easier to use, accommodate more documents, and meet the diverse needs of various departments—while still adhering to strict rules for privacy and safety.

Wired magazine also reported this week that the FDA has been in discussions with OpenAI regarding the use of AI. The report stated that a small OpenAI team and two individuals associated with Elon Musk’s Department of Government Efficiency have met with the FDA several times recently.

The FDA will continue to monitor the AI’s performance, solicit feedback from staff, and implement improvements. More information will be shared with the public in June.